Aerovate Therapeutics's total assets for Q3 2024 were $89.35M, a decrease of -20.01% from the previous quarter. AVTE total liabilities were $106.21M for the fiscal quarter, a 514.07% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.